Latest Conference Articles

Advantages of CPAD Consortium: Sudhir Sivakumaran, PhD; Klaus Romero, MD, MS, FCP

Advantages of CPAD Consortium: Sudhir Sivakumaran, PhD; Klaus Romero, MD, MS, FCP

July 28th 2021, 5:00pm

Alzheimer's Association International Conference

The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.

Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy

Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy

July 28th 2021, 3:00pm

Disease Spotlight: Multiple Sclerosis

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).

Relapse Rates and Effects of Dementia-Related Psychosis: Clive Ballard, MD

Relapse Rates and Effects of Dementia-Related Psychosis: Clive Ballard, MD

July 28th 2021, 1:00pm

Alzheimer's Association International Conference

Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.

Sildenafil Shows Potential as Alzheimer Disease Preventive Therapy

Sildenafil Shows Potential as Alzheimer Disease Preventive Therapy

July 27th 2021, 3:00pm

Alzheimer's Association International Conference

The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.

Pimavanserin in Dementia-Related Psychosis: Clive Ballard, MD

Pimavanserin in Dementia-Related Psychosis: Clive Ballard, MD

July 27th 2021, 1:00pm

Alzheimer's Association International Conference

Ballard, a professor of age related diseases at University of Exeter, discussed the results from a recent trial of pimavanserin in dementia-related psychosis, and data presented at this year’s AAIC meeting.

Gamma Sensory Stimulation Safe for Mild-to-Moderate AD

Gamma Sensory Stimulation Safe for Mild-to-Moderate AD

July 27th 2021, 11:00am

Alzheimer's Association International Conference

Findings presented at AAIC 2021 found that long-term, daily treatment with non-invasive stimulation was both safe and well-tolerated in patients with Alzheimer disease.

ARIA Events Most Often Asymptomatic in Aducanumab Treatment

ARIA Events Most Often Asymptomatic in Aducanumab Treatment

July 26th 2021, 9:00pm

Alzheimer's Association International Conference

Pooled data from the phase 3 clinical development of aducanumab (Aduhelm; Biogen) suggest that ARIA remains a mostly asymptomatic problem, with MRI providing an effective way to monitor events.

Gemfibrozil Shows Promise in Predementia Alzheimer Disease Metabolic and CVD Outcomes

Gemfibrozil Shows Promise in Predementia Alzheimer Disease Metabolic and CVD Outcomes

July 26th 2021, 7:00pm

Alzheimer's Association International Conference

The agent, which is FDA-approved for hyperlipidemia, showed significant improvements in plasma glucose, lipid levels, and trends in cardiovascular imaging biomarkers.

Ongoing Research in MS Differentiation: Oliver Tobin, MBBCh, BAO, PhD

Ongoing Research in MS Differentiation: Oliver Tobin, MBBCh, BAO, PhD

July 21st 2021, 9:00pm

Institutional Perspectives in Neurology: Multiple Sclerosis With Brian Weinshenker, MD

The associate professor of neurology at Mayo Clinic Rochester discusses technological advancements and research efforts in relation to differential multiple sclerosis.

Biomarkers and MRI Use in Patients With MS: Oliver Tobin, MBBCh, BAO, PhD

Biomarkers and MRI Use in Patients With MS: Oliver Tobin, MBBCh, BAO, PhD

July 21st 2021, 5:00pm

Institutional Perspectives in Neurology: Multiple Sclerosis With Brian Weinshenker, MD

The associate professor of neurology at Mayo Clinic Rochester, commented on biomarkers for identifying MS in patients, as well as the significance of new MS consensus guidelines.